You are here: Industry Insights > NCI

News List

Immune-Based Therapy Shows Promise Against Advanced Breast Cancers drugs.com
February 09, 2022
An experimental therapy that harnesses the body's tumor-fighting immune cells...
Lantern Pharma and NCI expand oncology partnership pharmaceutical-business-review
January 13, 2022
Lantern Pharma and the US National Institutes of Health unit National Cancer Institute’s (NCI) Developmental Therapeutics Branch (DTB) have announced...
Neogene Therapeutics signs global license agreement with NCI for cancer treatment drugs.com
January 12, 2022
Biotechnology firm Neogene Therapeutics has signed an exclusive, global license agreement with the National Cancer Institute (NCI) for a portfolio...
50 Years of Progress in Treating Patients with Cancer FDA
December 13, 2021
By Richard Pazdur, MD, Director, Oncology Center of Excellence (OCE) and Acting Director, Office of Oncologic Diseases (OOD)
Ascentage Pharma Establishes Cooperative R&D Agreement (CRADA) with the National Cancer Institute for Clinical Development of Ascentage Pharma's Drug Compound pelcitoclax prnasia
July 20, 2021
Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, announced that the company has entered into a Cooperative Research and Development Agreement ...
Vor Biopharma signs exclusive license pact with NCI for clinical-stage CD33 CAR-T expresspharma
November 12, 2020
It is currently being evaluated in a multi-site Phase 1/2 clinical trial in children and young adults with relapsed or refractory acute myeloid leukemia (AML).
7 Hills Pharma Receives NCI Grant for Immunostimulant Trials americanpharmaceuticalreview
September 23, 2020
7 Hills Pharma has been awarded a two-year, $2 million Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI) of the U.S. National Institutes of Health.
COVID-19 Update: FDA Shares Antibody Test Performance Data contractpharma
June 09, 2020
Independently evaluates certain antibody tests, including antibody tests that were not the subject of an EUA or pre-EUA, and those that were under FDA review.
Dose-adjusted chemotherapy regimen effective in Burkitt lymphoma trial europeanpharmaceuticalreview
May 29, 2020
Researchers reveal dose-adjusted (DA) EPOCH-R chemotherapy regimen was effective across all ages of Burkitt lymphoma patients in a Phase II clinical trial.
Half of Physician Directors of NCI Cancer Centers Receive Industry Payments drugs
August 16, 2019
In 2017, about half of physician directors of National Cancer Institute (NCI)-designated cancer centers received industry payments, according to a research letter published online in JAMA Internal Medicine.

Previous page 1 2 Next page